<DOC>
	<DOCNO>NCT02814409</DOCNO>
	<brief_summary>The principle research question : patient acute ischaemic stroke eligible intravenous ( IV ) thrombolysis , tenecteplase superior efficacy alteplase , base functional outcome assess modified Rankin Scale distribution day 90 ?</brief_summary>
	<brief_title>Alteplase-Tenecteplase Trial Evaluation Stroke Thrombolysis</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<mesh_term>Tenecteplase</mesh_term>
	<criteria>Inclusion criterion : Eligible intravenous thrombolysis . Male nonpregnant female â‰¥18 year age . &lt; 4.5h symptom onset . Consent patient legal representative . Independent prior stroke ( estimate modify Rankin Scale 01 ) . Exclusion criterion : Eligible intravenous thrombolysis : Evidence intracranial haemorrhage significant nonstroke intracranial pathology likely account clinical presentation represent risk intracerebral haemorrhage ( eg Central Nervous System neoplasm ) pretreatment computerise tomography ( CT ) scan ; Stroke within previous 14 day , thrombolytic therapy within past 14 day , hypodensity pretreatment computerise tomography ( CT ) scan consistent recent cerebral ischaemia present event ; Systolic blood pressure 185 diastolic blood pressure 110 mmHg , aggressive management ( intravenous pharmacotherapy ) necessary reduce blood pressure limit ; Clinical history suggestive subarachnoid haemorrhage even blood evident computerised tomography ( CT ) scan ; High risk haemorrhage , include major surgery , trauma gastrointestinal urinary tract haemorrhage within previous 21 day ; Arterial puncture noncompressible site within previous 7 day ; Prolonged cardiopulmonary resuscitation ( &gt; 2 minute ) within previous 14 day ; Acute pericarditis and/or subacute bacterial endocarditis ; acute pancreatitis ; Severe hepatic dysfunction , include hepatic failure , cirrhosis , portal hypertension ( oesophageal varix ) active hepatitis ; Active peptic ulceration ; Known history haemorrhagic stroke ; Known defect clot platelet function ( antiplatelet therapy ) ; Hypo hyperglycaemia ( blood glucose &lt; 2 mmol/l &gt; 18 mmol/l ) sufficient account neurological symptom ; Seizure onset symptom unless brain imaging identifies positive evidence significant brain ischaemia ( eg early ischaemic change hyperdense vessel plain computerise tomography ( CT ) scan , computerise tomography angiography ( CTA ) scan confirm arterial occlusion ) ; Pregnancy ( woman childbearing potential negative pregnancy test require prior randomisation ) ; Inadequate haemostasis : Taking warfarin international normalised ratio ( INR ) &gt; 1.3 , Taking Direct Oral Anticoagulant ( dabigatran , rivaroxaban , apixaban , edoxaban ) unless know &gt; 12 hour since last dose normal coagulation assay , Low molecular weight heparin ( dose prophylaxis venous thromboembolism ) administer within precede 48 hour , Unfractionated heparin administer within previous 48 hour activate partial thromboplastin time ( APTT ) prolong . Acute endovascular treatment stroke plan . Any major medical condition likely limit survival day 90 . Unavailable day 90 followup .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>